15
Table 8. CAR T-cell Therapies
Generic
Brand
Company Indication Dosing (IV infusion)
Tisagenlecleucel (tisa-cel)
Kymriah
®
Novartis
Pediatric and young
adult B-cell ALL (up to
25 years of age)
• 0.2–5.0 × 10
6
CAR-
positive viable T cells per
kg of body weight for
patients 50 kg or less, OR
• 0.1–2.5 × 10
6
CAR-
positive viable T cells for
patients more than 50 kg
Adult relapsed or
refractory diffuse large
B-cell lymphoma
0.6–6.0 × 10
8
CAR-positive
viable T cells
Axicabtagene ciloleucel
(axi-cel)
Yescarta
®
Gilead / Kite Pharma
Large B-cell lymphoma
Follicular lymphoma
2 × 10
6
CAR-positive viable
T cells per kg body weight
Brexucabtagene autoleucel
(brexu-cel)
Tecartus
®
Gilead / Kite Pharma
Mantle cell lymphoma 2 × 10
6
CAR-positive viable
T cells per kg body weight
Lisocabtagene maraleucel
(liso-cel)
Breyanzi
®
Bristol-Myers Squibb
Large B-cell lymphoma 50–110 × 10
6
CAR-positive
viable T cells
Idecabtagene vicleucel
(ide-cel)
Abecma
®
Bristol-Myers Squibb
Multiple myeloma 300–460 × 10
6
CAR-positive
T cells
